Thyrocare all set for rapid growth under the new leadership
Synopsis
Thyrocare is primarily a B2B diagnostic services provider. With PharmEasy’s presence, it will no longer be seen as a conventional diagnostic business but more of an online service play.
ET Intelligence Group: Thyrocare Technologies’ risk-reward ratio for investors is likely to improve after the acquisition by PharmEasy given a possibility of a high-growth phase under the new leadership and lower valuation compared with larger listed peers including Dr Lal PathLabs (DLPL) and Metropolis Healthcare. PharmEasy’s large online retail presence is expected to accelerate Thyrocare’s future growth albeit at a lower profitability
